Founded in 2008, Accelerated Medical Diagnostics, Inc., is a cancer diagnostics company with offices located in Dublin, CA and laboratory facilities in Davis, CA. At Accelerated Medical Diagnostics, we fuse expertise in cancer biology, drugs and diagnostics to develop objective, reproducible tests that provide clinicians with information to enhance patient care.
As a pioneer in the field of predictive chemotherapy diagnostics, the company is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on platinum-based chemotherapy for bladder, lung and breast cancer, Accelerated Medical Diagnostics is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of our test, called PlatinDx, which measures cellular responses to nontoxic “microdoses” of chemotherapy administered to patients.
Accelerated Medical Diagnostics is a privately held company funded predominantly by research contracts. We are developing the PlatinDx test through collaborations with university hospitals. Accelerated Medical Diagnostics is currently conducting two feasibility clinical trials with collaborators at UC Davis, UCLA, UCSF and USC.
Meet the Team
Paul is on the faculty of the UC Davis Department of Internal Medicine, where he lead the preclinical research that formed the foundation of the PlatinDx test.
Prior to UC Davis, Paul was a Biomedical Scientist at Lawrence Livermore National Laboratory from 2002-2008, where he worked on applying accelerator mass spectrometry to cancer research, which formed the technical foundation of PlatinDx.
Paul was an NIH postdoctoral fellow at the Massachusetts Institute of Technology from 1999-2001, where he studied DNA repair.
Paul received his PhD in Organic Chemistry from Georgia Tech in 1999 and his BS in Chemistry from the University of Florida in 1992.
He also serves as Associate Professor of Medicine at the UC Davis Department of Internal Medicine, Department of Hematology and Oncology.
From 1999 – 2002 he trained in a Medicine Internship and Residency at St. Francis Hospital, Evanston, IL.
Dr. Pan trained from 2002 – 2005 as a Fellow in Hematology/Oncology at Indiana University.
Prior to AMD, George was a co-founder and former Vice-President of Development of Cerus Corporation (NASDAQ-CERS). During his tenure, three global products were developed, approved in the EU, and are presently sold in Europe and the Middle East. The FDA granted PMAs for these products in 2014. Prior to Cerus, he co-founded a small diagnostic company where he managed research programs and partnerships with Cetus Corp, Chiron Corp, Eastman Kodak, Hoffman-La Roche, and Applied Biosystems.
George was an NIH post-doctoral fellow in the Chemistry Department at UC Berkeley, where he studied psoralen/nucleic acid photochemistry. He received his PhD in Molecular Biology and Biochemistry at UC Irvine, and an MA in Physics from Brandeis University.
Neil is providing strategic management guidance and pharmacoeconomic modeling of our diagnostic tests.
Our Advisory Board
AMD’s advisors are world leaders in clinical oncology and the commercialization of oncology diagnostics for personalized medicine. They are actively guiding the Management Team with the expertise required to bring predictive chemotherapy diagnostics into routine clinical practice.
Dr. de Vere White is Associate Dean for Cancer Programs at UC Davis School of Medicine, Director of the UC Davis Comprehensive Cancer Center and a Professor and Chair of the Department of Urology. He received his medical degree from Dublin University in Dublin, Ireland, and completed an internship and residencies in surgery and urology at St. Vincent’s Hospital in Dublin and at Duke University Medical Center in Durham, NC.
The author of more than 300 peer-reviewed scientific articles and book chapters, Dr. deVere White serves on the editorial boards of six international scientific journals. His current research efforts focus on the molecular events that govern the response of prostate and bladder cancer to targeted therapies, the biomolecular mechanisms that make some prostate cancers more virulent than others, and new methods of diagnosing and treating prostate cancer.
He is the immediate past president-elect of the Society of Urologic Oncology, a member of the Clinical Society of Genitourinary Surgeons and an elected member of the prestigious American Association of Genitourinary Surgeons.
Prior to joining Crescendo, he was Vice President of Sales & Marketing for Genomic Health, where over a 6-year period he led the commercial development and launch of Oncotype DX® for recurrence risk assessment in early-stage breast cancer in 2004. This pivotal launch remains a model for the sector, as this was the first such product to establish value-based pricing for a diagnostic service. Prior to that, he served in a range of commercial positions from strategic planning to business development to marketing and sales management at a number of leading biopharmaceutical companies, including ALZA, Amgen, Immunex, and Eli Lilly.
Ted began his career as a Naval Officer, serving as an aviator in the Western Pacific. Born and raised in Minneapolis, he received a B.S. in Economics from the University of Idaho and an M.B.A. in Marketing from the University of Michigan.